超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國(guó)Cubist Pharmaceuticals
Cubist Pharmaceuticals 總部位于馬薩諸塞州萊克星頓，是一個(gè)全球公司。在意大利設(shè)有工廠，在全球各地建立合作伙伴關(guān)系銷售 CUBICIN，在美國(guó)有銷售人員。Cubist Pharmaceuticals 每年收入超過(guò)一億九千萬(wàn)美元，員工逾 400 名，將一如既往地研制抗感染藥物。Cubist Pharmaceuticals 在納斯達(dá)克證券交易所上市（納斯達(dá)克代碼為：CBST）。

Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company is headquartered in Lexington, Massachusetts. In the U.S., Cubist markets CUBICIN? (daptomycin for injection), the first IV antibiotic from a class of antiinfectives called lipopeptides. Cubist employs more than 550 people. The company's total net revenues increased 47% to $433.6 million in 2008 from $294.6 million in 2007.

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
History
Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel antiinfectives for use in hospitals and other acute care environments.

Cubist completed its initial public offering (IPO) in 1996, and shares are listed on NASDAQ (ticker symbol: CBST). In 1997, at a time when most pharmaceutical companies had abandoned discovery and development of antibiotics, Cubist in-licensed daptomycin, a first-in-class cyclic lipopeptide antibiotic drug candidate, originally discovered by scientists at Eli Lilly, which had discontinued its work on daptomycin as a drug candidate. Based on a breakthrough by Cubist scientists, we resumed human trials with daptomycin in IV form and it was approved by the FDA as CUBICIN (daptomycin for injection) and launched in the U.S. in 2003. CUBICIN has to date experienced the most successful antibiotic launch in U.S. history, on a dollar sales basis. In 2005, Cubist submitted a sNDA seeking an expanded label for CUBICIN based on results of the Company's landmark Phase 3 trial studying the treatment of S.aureus bloodstream infections, including infective endocarditis. Following the positive recommendations of the Anti-infective Drugs Advisory Committee in March 2006, the FDA approved an expanded U.S. label for CUBICIN on May 25, 2006.